News Sentiment

CHRS sentiment intelligence

Coherus BioSciences Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 71 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.54 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

77/100 classification confidence.

Company focus 62

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend inactive

+6.2% over one week, +10.0% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

Coherus BioSciences stock stays supported by oncology focus

Market Reaction

Price moving ahead of tone

59/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 77/100 classification
One-week reaction 6.2% Price confirming higher
Trend fit Trend inactive 10.0% over four weeks
Fair value -15.1% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 15
Neutral 50
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 62
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
Stock Titan 11
Investing.com 7
TradingKey 5
TradingView 3
GlobeNewswire 3
simplywall.st 3
AD HOC NEWS 2

Event Lens

What the news is about

Classified themes
Market update 34
Earnings 29
Deals and strategy 4
Macro sensitivity 3
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 71
Ad-hoc-news.de Direct company coverage

Coherus BioSciences stock stays supported by oncology focus

Coherus BioSciences (CHRS) stock reflects the company's strategic shift towards immuno-oncology while maintaining a biosimilar portfolio. Investors are closely monitoring revenue generation from commercialized biosimilars, the company's cash position, and advancements in its onco

Tone
Positive 63/100
Event
Earnings
Published
09 Jul 2026 20:29
Source
Ad-hoc-news.de
AD HOC NEWS Direct company coverage

Coherus BioSciences focuses on biosimilars as investors watch Nasdaq listing

Coherus BioSciences is a biopharmaceutical company listed on Nasdaq, specializing in biosimilar and immuno-oncology products. The company aims to provide lower-cost alternatives to established branded therapies and is also developing innovative cancer treatments. Investors are wa

Tone
Positive 66/100
Event
Market update
Published
07 Jul 2026 12:06
Source
AD HOC NEWS
TradingView Direct company coverage

CHRS Forecast — Price Target — Prediction for 2027

The article provides a forecast and price target for Coherus Oncology, Inc. (CHRS) stock, outlining analysts' predictions and historical performance data. It details the company's current stock price, market capitalization, volatility, and future earnings estimates, alongside his

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 11:41
Source
TradingView
GlobeNewswire Direct company coverage

Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)

Coherus Oncology and Zumutor Biologics have announced a clinical collaboration and supply agreement for a Phase 1 trial evaluating ZM008, an anti-LLT1 monoclonal antibody, in combination with Coherus's PD-1 inhibitor, LOQTORZI. The study will enroll patients with various solid tu

Tone
Positive 70/100
Event
Macro sensitivity
Published
25 Jun 2026 10:39
Source
GlobeNewswire
TradingKey Direct company coverage

Coherus BioSciences Inc (CHRS) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Coherus BioSciences Inc (CHRS), noting its current valuation score of 9.20, which ranks 44th in the Pharmaceuticals industry. It highlights that the company's current P/E ratio is 0.85, significantly lower than its recent high but hig

Tone
Positive 59/100
Event
Market update
Published
18 Jun 2026 05:39
Source
TradingKey
TradingKey Direct company coverage

Coherus BioSciences Inc (CHRS) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Coherus BioSciences Inc (CHRS), identifying major individual and institutional holders, along with their respective proportions. It also presents a breakdown of shareholder types, including investment advisors, corporations, and h

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 00:39
Source
TradingKey
TradingKey Direct company coverage

Coherus BioSciences Inc (CHRS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Coherus BioSciences Inc (CHRS), categorizing its revenue by business segment and by region. For the reported period, UDENYCA accounted for the vast majority of revenue at 99.24%, followed by CIMERLI and YUSIMRY. Geographicall

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 20:39
Source
TradingKey
TradingKey Direct company coverage

Coherus BioSciences Inc (CHRS) Earnings Forecast: Future EPS & Revenue Growth Estimates

Coherus BioSciences Inc (CHRS) has an earnings forecast score of 8.57, ranking 27th in the Pharmaceuticals industry. Analysts have set an average price target of $5.00 for CHRS, with a "Buy" rating based on the consensus of seven analysts. The company's expected revenue for the n

Tone
Positive 73/100
Event
Earnings
Published
17 Jun 2026 13:10
Source
TradingKey
Investing.com Australia Direct company coverage

Coherus Oncology appoints PwC as new auditor, replaces Ernst & Young By Investing.com

Coherus Oncology has appointed PricewaterhouseCoopers LLP (PwC) as its new independent auditor, replacing Ernst & Young LLP, effective June 12, 2026. The change follows the dismissal of Ernst & Young by the Audit Committee, with Coherus Oncology stating no disagreements on accoun

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 09:09
Source
Investing.com Australia
Investing.com Direct company coverage

Coherus Oncology appoints PwC as new auditor, replaces Ernst & Young

Coherus Oncology has announced the dismissal of Ernst & Young LLP as its independent auditor, effective June 12, and the appointment of PricewaterhouseCoopers LLP (PwC) for the fiscal year ending December 31, 2026. The company stated that there were no disagreements on accounting

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 03:39
Source
Investing.com
Stock Titan Direct company coverage

[8-K] Coherus Oncology, Inc. Reports Material Event

Coherus Oncology, Inc. filed an 8-K report announcing a change in its independent auditing firm. On June 12, 2026, the company dismissed Ernst & Young LLP and appointed PricewaterhouseCoopers LLP for the fiscal year ending December 31, 2026, subject to standard acceptance procedu

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 03:02
Source
Stock Titan
Stock Titan Direct company coverage

Coherus Oncology (CHRS) director receives 30K RSUs and 60K stock option grant

Coherus Oncology director Ali J. Satvat was granted 30,000 restricted stock units (RSUs) and a stock option for 60,000 shares on June 5, 2026. The RSUs vest 100% on June 3, 2027, and the stock option, with an exercise price of $1.45, becomes fully exercisable on June 3, 2027. Bot

Tone
Neutral 50/100
Event
Market update
Published
10 Jun 2026 19:09
Source
Stock Titan
Stock Titan Direct company coverage

[Form 4] Coherus Oncology, Inc. Insider Trading Activity

This article reports on insider trading activity at Coherus Oncology, Inc. (CHRS) from a Form 4 filing. It details two transactions by insider Ryan Michael Lee, involving the grant of 30,000 shares of common stock and 60,000 stock options, both vesting over time. The filing impac

Tone
Neutral 50/100
Event
Market update
Published
09 Jun 2026 23:09
Source
Stock Titan
Investing.com Direct company coverage

Coherus Oncology shareholders approve director elections and equity plan changes

Coherus Oncology shareholders held their 2026 Annual Meeting, electing two Class III directors, Dennis M. Lanfear and Mats L. Wahlström, and ratifying Ernst & Young LLP as their independent public accounting firm. They also approved a non-binding advisory resolution on executive

Tone
Neutral 50/100
Event
Market update
Published
05 Jun 2026 17:09
Source
Investing.com
Stock Titan Direct company coverage

Coherus Oncology (CHRS) shareholders approve equity plan changes and option repricing

Coherus Oncology, Inc. shareholders approved all proposals at their 2026 annual meeting, including the election of Class III directors, ratification of Ernst & Young LLP as auditor, and a non-binding Say-on-Pay resolution. Key equity-related approvals included a reduction in the

Tone
Neutral 50/100
Event
Market update
Published
04 Jun 2026 01:10
Source
Stock Titan
Stock Titan Direct company coverage

Coherus (NASDAQ: CHRS) reprices 3.2M CEO stock options to $1.59

Coherus Oncology, Inc. announced the repricing of 3.2 million stock options for President & CEO Dennis M. Lanfear to an exercise price of $1.59 per share. These new options replace older ones with significantly higher exercise prices, a move approved by stockholders on May 29, 20

Tone
Neutral 50/100
Event
Market update
Published
03 Jun 2026 11:39
Source
Stock Titan
The Globe and Mail Direct company coverage

Coherus Biosciences Announces 2026 Stockholder Meeting Results

Coherus Biosciences (CHRS) announced the results of its 2026 Annual Meeting of Stockholders. Key outcomes include the election of Class III directors, ratification of Ernst & Young LLP as auditor, approval of executive compensation, and a reduction in the exercise price of certai

Tone
Neutral 50/100
Event
Earnings
Published
02 Jun 2026 22:39
Source
The Globe and Mail
Finviz Direct company coverage

CHRS - Coherus Oncology Inc Stock Price and Quote

This article provides comprehensive stock information for Coherus Oncology Inc. (CHRS), including its latest stock price, financial overview, analyst ratings, and recent news. Key data points cover market capitalization, P/E ratios, EPS, sales figures, and insider/institutional o

Tone
Neutral 50/100
Event
Earnings
Published
01 Jun 2026 10:10
Source
Finviz
Stock Titan Direct company coverage

Coherus Oncology (CHRS) CFO receives repriced $1.59 stock options, cancels higher-strike grants

Coherus Oncology's CFO, Bryan J. McMichael, received new stock options on May 29, 2026, with an exercise price of $1.59 per share, totaling 220,000 shares. Simultaneously, previously granted options with higher exercise prices, ranging from $5.44 to $14.76 per share, were dispose

Tone
Neutral 50/100
Event
Market update
Published
31 May 2026 14:40
Source
Stock Titan
AD HOC NEWS Direct company coverage

Coherus BioSciences stock (US19247A1007): short interest remains elevated as investors watch oncology pipeline

Coherus BioSciences (CHRS) continues to experience high short interest and volatile trading as investors assess its oncology and biosimilar portfolios. The company, a US biotechnology firm, is strategically shifting towards high-margin oncology assets while managing its legacy bi

Tone
Neutral 50/100
Event
Market update
Published
21 May 2026 02:10
Source
AD HOC NEWS
GlobeNewswire Direct company coverage

Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update

Coherus Oncology reported its first-quarter 2026 financial results, highlighting LOQTORZI® net revenue of $11.8 million, a 61% increase year-over-year. The company also provided updates on its pipeline, including the completion of patient accrual for the 1L HCC Phase 2 clinical t

Tone
Positive 67/100
Event
Earnings
Published
15 May 2026 16:40
Source
GlobeNewswire